La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Compass Therapeutics Bilan de santé

Santé financière contrôle des critères 6/6

Compass Therapeutics possède un total de capitaux propres de $146.1M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $155.6M et de $9.5M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$146.23m
Fonds propres	US$146.10m
Total du passif	US$9.51m
Total des actifs	US$155.61m

Mises à jour récentes de la santé financière

We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

Jun 05

We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely

Feb 13

Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth

Sep 20

Recent updates

We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

Jun 05

We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely

Feb 13

Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth

Sep 20

Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial

Oct 11

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de CMPX ( $153.5M ) dépassent ses passifs à court terme ( $9.5M ).

Passif à long terme: CMPX n'a pas de passif à long terme.

Historique et analyse du ratio d'endettement

Niveau d'endettement: CMPX est sans dette.

Réduire la dette: CMPX n'a aucune dette par rapport à il y a 5 ans, lorsque son ratio d'endettement était 53.9%.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: CMPX dispose d'une piste de trésorerie suffisante pour plus de 3 ans sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: CMPX dispose d'une marge de trésorerie suffisante pour plus de 3 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 8.8 % chaque année

Compass Therapeutics Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely

Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth

Recent updates

Price target decreased by 13% to US$8.00

Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 2500 Growth Index

We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

Compass Therapeutics, Inc. Announces Management Changes

Compass Therapeutics to Present Phase 1 Data for CTX-471, a Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

Compass Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Compass Therapeutics, Inc. Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated

Compass Therapeutics, Inc. Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors

New minor risk - Shareholder dilution

We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely

Compass Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective January 9, 2024

Compass Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective January 9, 2024

Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth

Ankyra Therapeutics Names Robert V. Tighe as Chief Scientific Officer

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Co-Founder recently bought US$80k worth of stock

Co-Founder recently bought US$77k worth of stock

Compass Therapeutics, Inc. Appoints David Wurzer as Class III Director, Member and Chairman of the Audit Committee

Price target increased to US$9.46

Compass Therapeutics, Inc. Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer

Compass Therapeutics, Inc. Announces That the First Patient Has Been Dosed in the Phase 1B Study of CTX-471 in Combination with Keytruda®, Merck’S Anti-PD-1 Therapy

President & COO recently sold US$97k worth of stock

Price target increased to US$9.67

High number of new and inexperienced directors

Compass Therapeutics, Inc. announced that it expects to receive $80.25 million in funding from a group of investors

Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial

High number of new and inexperienced directors

Compass Therapeutics, Inc. Announces Resignation of Stephen Squinto as Member of the Board of Directors, Effective August 31, 2022

High number of new and inexperienced directors

Co-Founder recently bought US$61k worth of stock

Co-Founder recently bought US$50k worth of stock

Compass Therapeutics, Inc. Reports Positive Interim Phase 2 Data of CTX-009 in Combination with Paclitaxel in Biliary Tract Cancers

High number of new and inexperienced directors

Price target decreased to US$8.86

Compass Therapeutics Announces Management Appointments

Compass Therapeutics, Inc. Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting

Compass Therapeutics, Inc. Announces Resignation of Brett Kaplan of the Board of Directors

Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)

High number of new and inexperienced directors

Compass Therapeutics, Inc. (OTCPK:CMPX) entered into a definitive merger agreement to acquire TRIGR Therapeutics, Inc. for $45.2 million.

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines